Patient disposition. ∗One patient completed scheduled daily pegcetacoplan dosing on day 339, and a follow-up exit visit at day 421 but was withdrawn from study and is therefore listed both as withdrawn and completed; ^†One patient in the wAIHA 270 mg group and 1 patient in the wAIHA 360 mg group were withdrawn from study by the investigator subsequent to discontinuation of study drug because of a TEAE.